EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs

Keiko Yamamoto iD, Kentaro Takeda iD, Hideki Maeda iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Keiko Yamamoto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Regulatory Science, Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoplasms, Drug Approval, Antineoplastic Agents, Molecular Targeted Therapy. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first global approval of a microsatellite instability‐high solid tumors was a landmark in oncology, paving the way for targeted therapies approved globally. However, guidance remains limited regarding the biological and methodological conditions under which such designs, statistical borrowing, are most effective. We retrospectively evaluated the feasibility of tumor‐agnostic development using Bayesian modeling based on the objective response rate (ORR) as the primary endpoint, focusing on single‐agent molecular targeted therapy (MTT) in Japan. Using Pharmaceuticals and Medical Devices Agency (PMDA) approval documents, we identified MTTs approved for ≥ 3 cancer types in Japan between 2001 and 2023. We analyzed whether their ORR in treatment lines without standard therapy exceeded thresholds using the beta‐binomial model (BBM) and hierarchical Bayesian model (HBM). Among 97 approved MTTs, 57 were for solid tumors or sarcomas, and 14 for ≥ 3 indications. Poly (ADP‐ribose) polymerase (PARP) inhibitors and human epidermal growth factor receptor 2 antibody‐drug conjugate (HER2 ADC) consistently exceeded thresholds in both models. In contrast, mechanistic target of rapamycin (mTOR) and vascular endothelial growth factor (VEGF) inhibitors showed generally consistent results across both models, although some exceeded the threshold while others did not, indicating considerable variability. This study evaluates single‐agent therapies using ORR as the primary endpoint; therefore, the findings may not apply to combination therapies or endpoints such as progression‐free survival or overall survival. Nevertheless, integrating Bayesian models and biological understanding can clarify when statistical borrowing is appropriate, particularly in biologically similar tumor types and improve interpretability and the strategic feasibility of basket trials in tumor‐agnostic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsDrug ApprovalAntineoplastic AgentsMolecular Targeted TherapyDrug DevelopmentHumansRetrospective StudiesBayes TheoremJapanEndpoint DeterminationTreatment Outcome

Stichwörter der Autor:innen

basket trialdrug developmentprecision medicinetumor‐agnostic

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Regulatory Science, Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University, Tokyo, Japan.
  • Genmab K.K., Tokyo, Japan.
  • Data Science, Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.

ORCID-Profile: Keiko Yamamoto, Kentaro Takeda, Hideki Maeda

Zitieren

APA

Yamamoto, K., Takeda, K., & Maeda, H. (2025). Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs. Clinical and Translational Science. https://doi.org/10.1111/cts.70313

Vancouver

Yamamoto K, Takeda K, Maeda H. Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs. Clinical and Translational Science. 2025. doi:10.1111/cts.70313

BibTeX
@article{Yamamoto2025,
  author = {Yamamoto, Keiko and Takeda, Kentaro and Maeda, Hideki},
  title = {Retrospective Analysis of Master Protocols in Tumor‐Agnostic Drug Development: Evaluation of Application to Single‐Agent Therapies With ORR as the Endpoint for Approval of Oncology Drugs},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70313}
}
Kostenlos starten →